Saxagliptin

Drugs

Volumn 69, Issue 15, 2009, Pages 2103-2114

  Dhillon, Sohita ^a   Weber, Juliane ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1; METFORMIN;

ARTICLE; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; GLUCAGON-LIKE PEPTIDE 1; GLYBURIDE; HUMANS; METFORMIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 74049094040     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11201170-000000000-00000     Document Type: Article

References (34)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009 Jan; 32 Suppl. 1: S62-7
2. World Health Organization. Diabetes: fact sheet (no. 312) [online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs312/en/ [Accessed 2009 Jun 24]
3. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009 Jan; 32 (1): 193-203
4. Rosenstock J, Zinman B. Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2007 Apr; 14 (2): 98-107
5. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999 Jun 2; 281 (21): 2005-12
6. Campbell RK. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus. Ann Pharmacother 2007 Jan; 41 (1): 51-60
7. Ahren B. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes Care 2007 Jun; 30 (6): 1344-50
8. Inzucchi SE, McGuire DK. New drugs for the treatment of diabetes. Part II: incretin-based therapy and beyond. Circulation 2008 Jan 29; 117 (4): 574-84
9. Bristol-Myers Squibb. Onglyza (saxagliptin) tablets: US prescribing information [online]. Available from URL: http://packageinserts.bms.com/pi/pi- onglyza.pdf [Accessed 2009 Aug 6]
10. Boulton DW, Geraldes M. Safety, tolerabilty, pharmacokinetics and pharmacodynamics of once-daily oral doses of saxagliptin for 2 weeks in type 2 diabetic and healthy subjects [abstract no. 606-P plus poster]. 67th Scientific Sessions of the American Diabetes Association; 2007 Jun 22-26; Chicago (IL)
11. Henry R, Smith S, Schwartz S, et al. β-cell stimulation by saxagliptin in patients with T2D [abstract no. 447-P plus poster]. 69th Annual Scientific Sessions of the American Diabetes Association; 2009 Jun 5-9; New Orleans (LA)
12. Patel CG, Li L, Komoroski BJ, et al. No effect of saxagliptin on QTc interval in healthy subjects [abstract no. 2072-PO]. 69th Annual Scientific Sessions of the American Diabetes Association; 2009 Jun 5-9; New Orleans (LA)
13. Wang A, Dorso C, Kopcho L, et al. Implications of the prolonged dissociation rate of saxagliptin, a highly potent and selective DPP4 inhibitor, on plasma DPP measurements [abstract no. 2088-PO]. Diabetes 2008 Jun; 57 Suppl. 1: A576-7
14. Fura A, Khanna A, Vyas V, et al. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections. Drug Metab Dispos 2009 Jun; 37 (6): 1164-71
15. Boulton D, Tang A, Patel C, et al. Pharmacokinetics of dipeptidyl pepetidase-4 inhibitor saxagliptin in subjects with renal impairment [abstract no. P357]. 11th European Congress of Endocrinology; 2009 Apr 25-29; Istanbul
16. Patel C, Castaneda L, Frevert U, et al. Single-dose pharmacokinetics and safety of saxagliptin in subjects with hepatic impairment compared with healthy subjects [abstract no. 537-P]. Diabetes 2008 Jun; 57 Suppl. 1: A160
17. Boulton DW, Goyal A, Li L, et al. The effects of age and gender on the single-dose pharmacokinetics and safety of saxagliptin in healthy subjects [abstract no. 551-P]. Diabetes 2008 Jun; 57 Suppl. 1: A164
18. Boulton DW, Adams D, Li L, et al. Magnesium and aluminum hydroxides plus simethicone, famotidine, or ome-prazole do not meaningfully affect the pharmacokinetics of saxagliptin in healthy subjects [abstract no. PIII-68]. Clin Pharmacol Ther 2008 Mar; 83 Suppl. 1: S92-3
19. Boulton DW, Li L, Patel CG, et al. No pharmacokinetic interaction between saxagliptin and digoxin in healthy subjects [abstract no. PIII-69]. Clin Pharmacol Ther 2008 Mar; 83 Suppl. 1: S93
20. Girgis S, Patel CG, Li L, et al. The effect of diltiazem on the pharmacokinetics of saxagliptin in healthy volunteers [abstract no. 72]. J Clin Pharmacol 2007; 47 (9): 1199
21. Boulton DW, Brenner E, Royzman K, et al. Effect of ketoconazole on the pharmacokinetics of saxagliptin in healthy sunjects [abstract no. 89]. J Clin Pharmacol 2007; 47(9): 1203
22. Patel C, Li L, Komoroscki B, et al. No meaningful drugdrug interaction between saxagliptin and glyburide in healthy subjects [abstract no. 212]. 36th Annual Meeting of the American College of Clinical Pharmacology; 2007 Sep 9-11; San Fransisco (CA)
23. Patel C, Li L, Komoroscki B, et al. No meaningful drugdrug interaction between saxagliptin and metformin in healthy subjects [abstract no. 213]. 36th Annual Meeting of the American College of Clinical Pharmacology; 2007 Sep 9-11; San Fransisco (CA)
24. Patel C, Li L, Komoroscki B, et al. No meaningful drugdrug interaction between saxagliptin and pioglitazone subjects [abstract no. 226]. 36th Annual Meeting of the American College of Clinical Pharmacology; 2007 Sep 9-11; San Fransisco (CA)
25. Girgis S, You X, Maurer C, et al. The effect of simvastatin on the pharmacokinetics of saxagliptin in healthy volunteers [abstract no. 28]. J Clin Pharmacol 2007; 47 (9): 1188
26. Rosenstock J, Aguilar-Salinas C, Klein E, et al. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin 2009; 25 (10): 2401-11
27. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008 May; 10 (5): 376-86
28. Jadzinsky M, Pfutzner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009 Jun; 11 (6): 611-22
29. DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diabetes Care 2009; 32 (9): 1649-55
30. Chacra AR, Tan GH, Apanovitch A, et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonyl-urea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009 Jul 15; 63 (9): 1395-406
31. Allen E, Hollander P, Li J, et al. Saxagliptin added to a thiazolidinedione improves glycaemic control in patients with inadequately controlled type 2 diabetes [abstract no. 859]. Diabetologia 2008; 51 Suppl. 1: S342-3
32. Defronzo RA, Hissa MN, Garber AJ, et al. Once-daily saxagliptin added to metformin provides sustained gly-cemic control and is well tolerated over 102 weeks in patients with T2D [abstract no. 547-P]. 69th Annual Scientific Sessions of the American Diabetes Association; 2009 Jun 5-9; New Orleans (LA)
33. Chen R, Donovan M, Rusnak JM, et al. Saxagliptin used as monotherapy or in combination with other anti-hyperglycaemic agents does not significantly increase risk of hypoglycaemia [abstract no. 2082-PO]. 69th Annual Scientific Sessions of the American Diabetes Association; 2009 Jun 5-9; New Orleans (LA)
34. Wolf R, Frederich R, Fiedorek F, et al. Evaluation of CV risk in saxagliptin clinical trials [abstract no. 8-LB plus poster]. 69th Annual Scientific Sessions of the American Diabetes Association; 2009 Jun 5-9; New Orleans (LA)